Nonalcoholic Steatohepatitis (NASH)
16-03-2024
10:24 AM
1 min read
Overview:
Madrigal Pharmaceuticals Inc.’s drug Rezdiffra gained the first US approval to treat a potentially deadly liver disease called nonalcoholic steatohepatitis, or NASH that affects millions worldwide.
About Nonalcoholic Steatohepatitis (NASH)
- It is liver inflammation and damage caused by a buildup of fat in the liver.
- It is part of a group of conditions called nonalcoholic fatty liver disease.
- NASH can get worse and cause scarring of the liver, which leads to cirrhosis. But the disease doesn't always get worse.
- It is similar to the kind of liver disease that is caused by long-term, heavy drinking. But NASH occurs in people who don't abuse alcohol.
- Symptoms: As NASH progresses and liver damage gets worse, you may start to have symptoms such as:
- Fatigue (feeling tired all the time).
- Weight loss for no clear reason.
- General weakness.
- An ache in the upper right part of your belly.
- Causes: Things that put people at risk for NASH and for liver damage include: obesity, Insulin resistance and type 2 diabetes, high cholesterol and high triglycerides, metabolic syndrome etc.
- Treatment for NASH includes managing conditions that increase your risk for NASH or make it worse. You can:
- Reduce your total cholesterol level.
- Reach a healthy weight. Losing 3% to 10% of your total body weight can make a difference.
- Control diabetes.
Q1) What is the function of liver?
The liver is a critical organ in the human body that is responsible for an array of functions that help support metabolism, immunity, digestion, detoxification, vitamin storage among other functions.
Source: First drug to treat common, lethal liver disease gets US nod